Systemic anti-inflammatory versus fluocinolone acetonide intraocular implant
Reviewed by Brian Ang

In the Multicenter Uveitis Steroid Treatment (MUST) trial, 255 patients with intermediate uveitis, posterior uveitis or panuveitis were randomised to either fluocinolone acetonide intraocular implant or systemic corticosteroid therapy which was supplemented with immunosuppression if required. Patients were followed up for 54 months. Visual outcomes were similar in both groups at 54 months. However, the implant was better at controlling inflammation at every time point. Macular oedema improved significantly initially following implant insertion, but over time (36 months), the systemic group achieved similar improvements. It is therefore reasonable to consider the implant for unilateral cases and systemic therapy for bilateral cases.

Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis. Fifty-four-month results of the Multicentre Uveitis Steroid Treatment (MUST) Trial and follow-up study.
Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group.
OPHTHALMOLOGY
2015;122:1967-75.